The landscape of targeted therapies in TNBC

Elena Vagia*, Devalingam Mahalingam, Massimo Cristofanilli

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

179 Scopus citations


Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice.

Original languageEnglish (US)
Article number916
Issue number4
StatePublished - Apr 2020


  • DNA damage repair
  • Molecular profiling
  • Personalized medicine
  • Targeted treatment
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The landscape of targeted therapies in TNBC'. Together they form a unique fingerprint.

Cite this